Efficacy and Tolerability of Methotrexate and Methylprednisolone in a Comparative Assessment of the Primary and Long-Term Outcomes in Patients with Pulmonary Sarcoidosis

作者
Volodymyr Gavrysyuk,Ievgeniia Merenkova,Yaroslav Dziublyk,N. D. Morska,N. V. Pendalchuk,O. V. Bychenko,Н. А. Власова
出处
期刊:Diagnostics [Multidisciplinary Digital Publishing Institute]
卷期号:11 (7): 1289-1289 被引量:30
标识
DOI:10.3390/diagnostics11071289
摘要

Background: There is insufficient information in the literature on the comparative efficacy and tolerability of methotrexate (MTX) and methylprednisolone (MP) in patients with pulmonary sarcoidosis in assessing primary outcomes and the relapse rate. Purpose: The aim of our study was to evaluate primary and long-term outcomes of using MTX and MP in patients with pulmonary sarcoidosis. Methods: A total of 143 patients with newly diagnosed pulmonary sarcoidosis, verified by high-resolution computed tomography (CT) data, were examined. Corticosteroid (CS) therapy was used in 97 patients using MP at a dose of 0.4 mg/kg body weight for 4 weeks, followed by a dose reduction to 0.1 mg/kg by the end of the sixth month. The total duration of CS therapy was 12 months on average. Forty-six patients were treated with MTX at a dose of 10 mg/week (28) and 15 mg/week (18) per os for 6 to 12 months. The study of the relapse rate was conducted within 12 months after the CT data normalization in 60 patients after CS therapy and in 24 after MTX treatment. Results: MP treatment was successfully completed in 68 (70.1%), and MTX in 29 (60.4%) patients. In five MP patients (5.2%) and in five (10.9%) MTX, treatment was discontinued due to serious side effects. In seven (7.2%) MP patients and ten (21.7%) MTX patients, treatment required additional therapy due to the lack of efficacy. Progression with MP treatment (17–17.5%) was more common than with MTX (2–4.3%; Chi square = 4.703, p = 0.031). Relapses after MP therapy were observed in 26 (43.3%) patients, and after MTX therapy in 2 (8.3%; Chi square = 9.450, p = 0.003). Conclusion: In patients with pulmonary sarcoidosis, MTX monotherapy does not differ significantly from MP monotherapy in terms of the level of efficacy and the rate of serious side effects. Increasing the MTX dose from 10 to 15 mg/week accelerates the rate of regression of sarcoidosis, improves treatment efficacy, and does not affect the rate of serious side effects. When using MTX, there is a significant decrease in the incidence of treatment resistance and the relapse rate.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Helen完成签到,获得积分10
1秒前
安静怜雪完成签到,获得积分10
1秒前
刘较瘦完成签到,获得积分10
1秒前
好运爆彭完成签到,获得积分10
2秒前
樊小雾完成签到,获得积分10
2秒前
Qinzhiyuan1990完成签到 ,获得积分10
2秒前
爱科研的Z完成签到,获得积分10
3秒前
princesun083完成签到,获得积分10
3秒前
ZeKaWa的应助被发呆采纳,获得10
3秒前
玩命的灵安完成签到,获得积分10
3秒前
科研通AI65的应助被月九采纳,获得10
4秒前
4秒前
汉堡包的应助被完美的映秋采纳,获得30
4秒前
5秒前
zhugeliu完成签到,获得积分10
5秒前
skmksd完成签到,获得积分10
5秒前
QIEZI完成签到 ,获得积分10
5秒前
万能图书馆的应助被zzx采纳,获得10
5秒前
小虫发布了新的文献求助10
5秒前
科研通AI6.4的应助被长风入林采纳,获得10
6秒前
6秒前
点点完成签到 ,获得积分10
7秒前
satellite完成签到,获得积分10
7秒前
7秒前
8秒前
YuLu完成签到 ,获得积分10
9秒前
张颖涛完成签到,获得积分10
9秒前
9秒前
高贵的大蒜完成签到 ,获得积分10
10秒前
suifeng91完成签到,获得积分10
10秒前
一棵树发布了新的文献求助10
10秒前
宁静完成签到 ,获得积分10
10秒前
yujuan完成签到,获得积分10
11秒前
拉扣完成签到,获得积分10
11秒前
长脚蟹完成签到,获得积分10
12秒前
金勇完成签到,获得积分10
12秒前
英姑的应助被elang采纳,获得10
13秒前
13秒前
dougsong发布了新的文献求助10
13秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180146
求助须知:如何正确求助?哪些是违规求助? 9570319
关于积分的说明 21809739
捐赠科研通 7776294
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479039